Icosapent Ethyl Cuts Hospitalizations by 9% and Days Lost by 7%
A post hoc analysis of 8,179 statin-treated REDUCE-IT participants found that 2 g twice daily icosapent ethyl reduced total hospitalizations by 9% (HR 0.91; P=0.017). Patients on treatment had 12% greater odds of hospitalization-free survival (OR 1.12; P=0.016) and 7% fewer days lost to hospitalization or death (RR 0.93; P<0.001).
1. Analysis Overview
The post hoc analysis evaluated 8,179 statin-treated REDUCE-IT participants with elevated triglycerides and either known CVD or diabetes plus risk factors. Subjects were randomized to receive 2 g of icosapent ethyl twice daily or placebo and followed for a median of five years to assess total hospitalization events.
2. Key Findings
Treatment with icosapent ethyl lowered total hospitalizations by 9% (HR 0.91; P=0.017), increased the likelihood of remaining hospitalization-free by 12% (OR 1.12; P=0.016), and reduced days lost to hospitalization or death by 7% (RR 0.93; P<0.001).
3. Implications for Patients and Amarin
Fewer and shorter hospital stays can improve patient quality of life and reduce healthcare costs, strengthening the value of VASCEPA/VAZKEPA. These results may support broader adoption by payers, inclusion in clinical guidelines, and drive long-term sales growth for Amarin.